Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1522282 (
EMT
)
2,868
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently SPAG9 has been reported to show aberrant expressions in numerous human malignancies and act as a crucial role in tumor's proliferation and invasion. Human
enhancer of filamentation 1
(
HEF1
, also known as CasL and NEDD9) is a non-catalytic scaffolding protein belonging to CAS (Crk-associated substrate) protein family that interacts with multiple signaling cascades. Due to the diversified function of
HEF1
, abnormal expression of
HEF1
frequently combines with malignant phenotypes and poor prognosis. However, little is known between the relationship of SPAG9 and
HEF1
in bladder tumorigenesis. In this study, expression of SPAG9 in vivo and in vitro has been detected by quantitative real-time PCR and Western blot analysis after transfected with SPAG9 overexpression/inhibitor vector. We also found that
HEF1
expression shows consistency and is regulated by SPAG9. Overexpression of SPAG9 promotes bladder cancer cells migration through
HEF1
upregulation and emerges protein level of activated Rac1. Silencing SPAG9 inhibits cell migration through
HEF1
downregulation and reduces protein level of activated Rac1. Also, we found that expression of
EMT
marker such as E-cadherin, Vimentin is regulated by SPAG9. Considering
EMT
plays a crucial role in tumor cells spreading and invasion, SPAG9 and
HEF1
may potentially set a new therapeutic approach to bladder cancer treatment.
...
PMID:SPAG9 regulates HEF1 expression and drives EMT in bladder transitional cell carcinoma via rac1 signaling pathway. 3066 4